These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 9458092

  • 1. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
    Selig RA, White L, Gramacho C, Sterling-Levis K, Fraser IW, Naidoo D.
    Cancer Res; 1998 Feb 01; 58(3):473-8. PubMed ID: 9458092
    [Abstract] [Full Text] [Related]

  • 2. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2009 Feb 01; 33(5):323-31. PubMed ID: 19814678
    [Abstract] [Full Text] [Related]

  • 3. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Feb 01; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Feb 01; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 5. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Feb 01; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 6. Combined therapy with deferoxamine and deferiprone.
    Kattamis A.
    Ann N Y Acad Sci; 2005 Feb 01; 1054():175-82. PubMed ID: 16339663
    [Abstract] [Full Text] [Related]

  • 7. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Feb 01; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 8. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Feb 01; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 9. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Feb 01; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 10. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K, Pyar K, Wonke B.
    Med J Malaysia; 2000 Dec 01; 55(4):493-7. PubMed ID: 11221163
    [Abstract] [Full Text] [Related]

  • 11. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Dec 01; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 12. Chelation of bismuth by combining desferrioxamine and deferiprone in rats.
    Tubafard S, Fatemi SJ.
    Toxicol Ind Health; 2008 May 01; 24(4):235-40. PubMed ID: 19022876
    [Abstract] [Full Text] [Related]

  • 13. Iron withdrawal strategies fail to prevent the growth of SiHa-induced tumors in mice.
    Simonart T, Boelaert JR, Andrei G, Clercq ED, Snoeck R.
    Gynecol Oncol; 2003 Jul 01; 90(1):91-5. PubMed ID: 12821347
    [Abstract] [Full Text] [Related]

  • 14. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
    Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA, Giua R, Sebastio AM, Suma V, De Marco S, Semeraro F, Moscogiuri R.
    Haematologica; 1998 Jun 01; 83(6):496-501. PubMed ID: 9676021
    [Abstract] [Full Text] [Related]

  • 15. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
    Hemoglobin; 2008 Jun 01; 32(1-2):17-28. PubMed ID: 18274979
    [Abstract] [Full Text] [Related]

  • 16. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, Kalinowski DS, Kovacevic Z, Lovejoy DB, Richardson DR.
    Mol Pharmacol; 2013 Jan 01; 83(1):179-90. PubMed ID: 23074173
    [Abstract] [Full Text] [Related]

  • 17. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Jan 01; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 18. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Jan 01; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 19. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 20. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.
    Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, Gelfand E, Seligman P.
    Cancer Res; 1993 Sep 01; 53(17):3968-75. PubMed ID: 8358725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.